| 3 | Coronavirus Disease 2019 and Liver Injury:A Retrospective Analysis of Hospitalized Patients in New York City显示文摘Background and Aims:Coronavirus disease 2019(COVID-19)is a global threat,affecting more than 100 million people and causing over 2 million deaths.Liver laboratory test abnormalities are an extrapulmonary manifestation of COVID-19,yet characterization of hepatic injury is incomplete.Our objective was to further characterize and identify causes of liver injury in patients with COVID-19.Methods:We conducted a retrospective cohort study of 551 patients hospitalized with COVID-19 at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center between March 1,2020 and May 31,2020.We analyzed patient demographics,liver laboratory test results,vital signs,other relevant test results,and clinical outcomes(mortality and intensive care unit admission).Results:Abnormal liver laboratory tests were common on hospital admission for COVID-19 and the incidence increased during hospitalization.Of those with elevated serum alanine aminotransferase and/or alkaline phosphatase activities on admission,58.2%had a cholestatic injury pattern,35.2%mixed,and 6.6%hepatocellular.Comorbid liver disease was not associated with outcome;however,abnormal direct bilirubin or albumin on admission were associated with intensive care unit stay and mortality.On average,patients who died had greater magnitudes of abnormalities in all liver laboratory tests than those who survived.Ischemic hepatitis was a mechanism of severe hepatocellular injury in some patients.Conclusions:Liver laboratory test abnormalities are common in hospitalized patients with COVID-19,and some are associated with increased odds of intensive care unit stay or death.Severe hepatocellular injury is likely attributable to secondary effects such as systemic inflammatory response syndrome,sepsis,and ischemic hepatitis. | Joshua M.Bender Howard J.Worman | 2021 | Journal of Clinical and Translational Hepatology2021，9，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员